• Explore /
  • Poster
  • / Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

Abstract Poster

Authors

null

Guillem Argilés

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Guillem Argilés , Rodrigo Dienstmann , Marta Benavent Viñuales , Andres Cervantes , Susana Rosello Keranen , Ulla H. Hansen , Niels Jorgen Ostergaard Skartved , Ivan David Horak , Stephan Braun , Rocio Garcia Carbonero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01117428

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3551)

DOI

10.1200/jco.2014.32.15_suppl.3551

Abstract #

3551

Poster Bd #

14

Abstract Disclosures

Similar Posters

Poster

2019 Gastrointestinal Cancers Symposium

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.

First Author: Kristen Keon Ciombor

First Author: David S. Hong

First Author: John H. Strickler

First Author: Thomas H. Cartwright